There were 2 early large clinical trials, the 1998 Kirsten Ras Mutations in Patients With Colorectal Cancer (RASCAL) study11 and 2001 RASCAL II study,12 that were among the first to demonstrate the prognostic role of KRAS sequence variation in CRC. This evidence concerns the gene KRAS and colorectal cancer.